Rheumatology Advance Access originally published online on April 2, 2007
Rheumatology 2007 46(5):736-741; doi:10.1093/rheumatology/kem034
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
REVIEWS |
Anti-TNF therapy in the management of Behçet's disease—review and basis for recommendations
Athens University, Greece, 1Akdeniz University, Turkey, 2Alexandria University, Egypt, 3Paris IV University, France, 4Istanbul University, Turkey, 5Hokkaido University, Japan, 6Reggio Emilia Hospital, Italy, 7Elizabethenians' Hospital Klagenfurt, Austria, 8King's College, London, UK and 9Dessau Medical Center, Germany.
Correspondence to: P. P. Sfikakis, 18, Ipsilantou Str., Athens, 10676, Greece. E-mail: psfikakis@med.uoa.gr
| The first 150 words of the full text of this article appear below. |
 |
Introduction |
|---|
Behçet's disease (BD) is a multisystem, chronic-relapsing, inflammatory disorder classified among the vasculitides [1, 2]. It has a worldwide distribution being more prevalent in the Middle East, Far East and the Mediterranean basin [3]. The diagnosis is entirely based on clinical grounds since no pathognomonic laboratory findings exist. International study group classification criteria used for BD patients participating in research protocols depend on the presence of recurrent oral ulceration plus any two of the following: recurrent genital ulcerations, ocular lesions (anterior or posterior uveitis, or cells in the vitreous on slit lamp examination, or retinal vasculitis), typical skin lesions (erythema nodosum, pseudofollicullitis) and a positive pathergy (skin hyperreactivity) test [4, 5]. The clinical picture of BD is diverse and while recurrent mucocutaneous lesions are usually the only symptoms at the onset of the disease, most patients develop ocular and/or articular, vascular, central
|
Limitations of current therapies and unmet medical needs in Behçet's disease |
|---|
|
Anti-TNF agents in Behçet's disease: the current evidence |
|---|
Infliximab
Etanercept
Adalimumab
Safety issues
|
Anti-TNF agents in Behçet's disease: recommendations for optimal use |
|---|
Identification of patients likely to benefit from anti-TNF treatment
Selection of anti-TNF agent, monitoring and treatment adjustments
Infliximab for ocular disease
|
Anti-TNF agents in Behçet's disease: caution considerations |
|---|
|
Summary and conclusions |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Iwata, K. Saito, K. Yamaoka, S. Tsujimura, M. Nawata, K. Suzuki, and Y. Tanaka Effects of anti-TNF-{alpha} antibody infliximab in refractory entero-Behcet's disease Rheumatology, August 1, 2009; 48(8): 1012 - 1013. [Full Text] [PDF]
|
|
|
|
|
|
T. Yoshimura, K.-H. Sonoda, N. Ohguro, Y. Ohsugi, T. Ishibashi, D. J. Cua, T. Kobayashi, H. Yoshida, and A. Yoshimura Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis Rheumatology, April 1, 2009; 48(4): 347 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Ahn, H.-S. Cha, E.-M. Koh, S.-H. Kim, Y. G. Kim, C.-K. Lee, and B. Yoo Behcet's disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8 Rheumatology, August 1, 2008; 47(8): 1228 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hatemi, M. Melikoglu, N. Sut, and H. Yazici Purified protein derivative reaction is not augmented in Behcet's syndrome patients Rheumatology, May 1, 2008; 47(5): 733 - 734. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Giansanti, M. Ramazzotti, L. Vannozzi, E. Rapizzi, T. Fiore, B. Iaccheri, D. Degl' Innocenti, D. Moncini, and U. Menchini A Pilot Study on Ocular Safety of Intravitreal Infliximab in a Rabbit Model Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1151 - 1156. [Abstract] [Full Text] [PDF]
|
|